DR. MICHAEL LEONARD DURCI, M.D.

Plain English
This study looked at how the compact proton therapy system has been used over ten years at a cancer center in Louisiana. They found that from September 2014 to September 2024, 1,382 treatments were given, with 188 treatments in the last year, showing consistent use despite challenges like the COVID-19 pandemic. Most of the patients treated had prostate cancer and lived close to the center, and the study noted a trend towards fewer treatment sessions over time, which can reduce the burden on patients. Who this helps: This benefits cancer patients by providing effective and accessible treatment options.

Plain English
This study looked at how effective proton beam radiation therapy (PBT) is for patients with advanced pancreatic cancer that cannot be operated on. It involved 19 patients, who received a specific dose of radiation and were monitored for side effects and survival rates. The results showed that most patients tolerated the treatment well, with a median overall survival of about 14.6 months and a low recurrence rate of 81.7% at two years, indicating that PBT can control the disease effectively. Who this helps: This benefits patients with unresectable pancreatic cancer and their doctors by providing a potentially better treatment option.

Plain English
This study looked at a new type of radiation therapy called hypofractionated proton beam radiotherapy (PBT) for patients with liver tumors that could not be surgically removed. Researchers treated 63 patients and found that 91.2% of patients with hepatocellular carcinoma (HCC) and 90.9% of those with intrahepatic cholangiocarcinoma (ICC) had good control of their tumors after one year. The therapy was effective with low side effects, which is important for patients whose tumors are difficult to treat. Who this helps: This helps patients with inoperable liver tumors and their doctors.

Plain English
This study examined the effectiveness of a treatment called stereotactic body radiation therapy (SBRT) for patients with early-stage non-small cell lung cancer (NSCLC), comparing those diagnosed through biopsy to those diagnosed based on imaging. The researchers analyzed the records of 88 patients and found that both groups had similar outcomes: after 3 years, about 93% of biopsy patients and 94% of imaging patients did not have local cancer progression, and the overall survival rates were around 60% for both groups. This is important because it shows that patients who cannot have a biopsy and are diagnosed by imaging can still receive effective treatment. Who this helps: This helps patients who cannot undergo biopsy, allowing them to access effective cancer treatment.

Plain English
This study looked at a specific type of radiation therapy called helical SBRT, used to treat early-stage lung cancer in 79 patients. The results showed that the treatment was highly effective, with a local control rate of 93.6% and a 3-year survival rate of 58.4%. Patients receiving a higher dose of radiation (60 Gy) had better survival rates than those who received a lower dose (65.2% compared to 37.5%). Who this helps: Patients with early-stage non-small cell lung cancer.

Plain English
This study looked at how different patient and tumor characteristics affect survival rates in people with early-stage non-small cell lung cancer treated with a specialized radiation therapy called helical stereotactic body radiotherapy (SBRT). It found that overall survival after three years was 53.4% for all patients, but it varied significantly based on tumor stage—64.4% for those with Stage IA and only 32.1% for Stage IB. Additionally, smaller tumors (less than 30 mm) had better survival rates compared to larger ones. Understanding these factors is important because it helps doctors predict outcomes and tailor treatment plans for patients. Who this helps: This helps patients with non-small cell lung cancer and their doctors.

Plain English
This study compared two devices used to measure radiation therapy profiles: the TomoScanner™ 2D Water Phantom and the IBA Helix. Researchers found that the IBA Helix provided measurements closely matching those from the TomoScanner, with differences of less than 1% at various depths, but showed up to 3% variance at a shallow depth. Understanding these differences is crucial for ensuring accurate radiation delivery in cancer treatments. Who this helps: This research benefits doctors and radiologists who ensure precise radiation treatment for cancer patients.

Plain English
This study examined how well different types of scanners—specifically commercial-grade and medical-grade scanners—work for analyzing radiochromic EBT film used in radiation dose measurement. The researchers tested four scanners and found that the Vidar scanner performed the best overall, with a repeatability uncertainty of just 0.1% and the ability to distinguish between 3.38 optical density levels, while the least effective scanner, the ScanMaker 8700, had a maximum distinguishable level of only 1.32 and a 20% uncertainty in dose ranges. These findings are important because they can help improve the accuracy of radiation dose measurements, which is crucial for patient safety in medical treatments. Who this helps: This helps patients receiving radiation therapy by ensuring more precise treatment dosages.

Plain English
This study looked at a rare and aggressive heart tumor called primary cardiac angiosarcoma, focusing on a 35-year-old woman who had surgery to remove the tumor and followed it up with radiation therapy. Although she initially did well and had no symptoms for eight months, the cancer spread to her bones and other areas after that time. This matters because it highlights the challenges of treating this type of tumor and the high likelihood of it spreading even after initial treatment. Who this helps: This helps patients with cardiac angiosarcoma and their doctors by providing insights into treatment outcomes.

Plain English
This study looked at three patients aged 46 to 83 who had subungual squamous cell carcinoma, a type of skin cancer under the nail, and were treated with radiation therapy instead of having their finger amputated. All three patients remained cancer-free for up to 52 months, and they were able to fully use their fingers afterward. This research is important because it shows that radiation therapy can effectively treat this type of cancer without the need for amputation, potentially preserving patients' quality of life. Who this helps: Patients with subungual squamous cell carcinoma who want to avoid amputation.